美金刚治疗镰状细胞病:为期1年对其认知功能与神经加工影响的研究
这项II期临床研究评估14名镰状细胞病青少年及年轻成人(平均年龄24岁)接受1年美金刚治疗的神经认知与电生理效应。治疗前及治疗后采用韦氏智力量表分测验和伴随事件相关电位记录的任务切换范式评估。美金刚治疗改善了认知测试表现,尤其处理速度,并降低了任务切换错误率,额叶与顶叶P1、P3波幅变化提示神经加工更高效。
要点
- 美金刚治疗1年后,数字符号编码与符号搜索测验显示处理速度改善。
- 任务切换测验错误率降低,提示认知负荷下降与执行控制增强。
- 额叶与顶叶P1、P3波幅变化提示认知灵活性任务中神经加工更高效。
核心结论
- 这些II期临床研究的初步发现作为概念验证,探索了美金刚治疗镰状细胞病的可行性与潜在有效性,支持开展更广泛研究以确认结果并评估美金刚的更广泛有效性。
研究设计与样本
- II期临床研究,纳入14名镰状细胞病(包括镰状细胞贫血和镰状细胞β-地中海贫血)青少年及年轻成人,平均年龄24岁,接受1年美金刚治疗。
- 治疗前后采用韦氏智力量表分测验和伴随事件相关电位记录的任务切换范式进行评估。
主要发现
- 美金刚治疗增强了认知测试表现,尤其体现在数字符号编码和符号搜索测验所反映的处理速度上。
- 结果提示视空间与书写运动速度、工作记忆和注意力改善。
- 任务切换测验显示错误率降低,提示认知负荷下降和执行控制增强。
- 治疗后额叶与顶叶位置P1和P3波幅的电生理变化提示需要认知灵活性的任务中神经加工更高效。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文称这些为II期临床研究的初步发现,作为概念验证。
- 原文称需要更广泛的研究来确认这些结果并评估美金刚的更广泛有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study evaluates the neurocognitive and electrophysiological effects of 1-year memantine treatment in 14 adolescents and young adults (mean age 24 years) with sickle cell disease (SCD, incluing sickle cell anaemia and sickle cell β-thalassemia), hypothesizing improvements in cognitive functions and neural processing. Participants underwent assessments using subtests from the Wechsler Intelligence Scale and a computerized task-switching paradigm with concurrent event-related potential (ERP) recordings, both before and after the treatment period. Assessments focused on processing speed, working memory, attention and executive function. ERP measurements targeted brain response changes during task switching. Memantine treatment enhanced cognitive test performance, especially in processing speed as shown by the Digit-Symbol Coding and Symbol-Search tests. Results indicated improved visuospatial and graphomotor speed, working memory and attention. The task-switching test revealed reduced error rates, suggesting decreased cognitive load and enhanced executive control. Electrophysiological changes in P1 and P3 amplitudes at frontal and parietal locations post-treatment pointed to more efficient neural processing in tasks requiring cognitive flexibility. These preliminary findings from a Phase II clinical study serve as a 'proof of concept', exploring the feasibility and potential effectiveness of memantine treatment in SCD-a previously uninvestigated context. They support the rationale for more extensive investigations to confirm these results and assess memantine's broader effectiveness.
引用
- Raz S, Koren A, Bogdanova AY, et al. Memantine treatment in sickle cell disease: A 1-year study of its effects on cognitive functions and neural processing. Br J Haematol. 2024. PMID: 39497557. doi:10.1111/bjh.19866
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。